Houston Methodist Hospital

Houston Methodist Hospital

Houston Methodist Hospital is a hospital and research facility located in Houston, Texas.

COVID-19 Response

Houston Methodist has set up a coronavirus resource center and has mobilized its RNA research group to identify possible preventative measures and treatments for SARS-CoV-2, the virus which causes the disease COVID-19.

COVID-19 Vaccine Research Partnership

Houston Methodist researchers are partnering with GeneOne Life Science Inc. to develop an RNA vaccine against COVID-19, the novel coronavirus that has caused a global pandemic. Houston Methodist developed an RNA therapeutics research program to design, manufacture and test clinical-grade RNA. GeneOne, based in Seoul, South Korea, established its Texas-based manufacturing subsidiary VGXI to build expertise in generating pre-clinical through Current Good Manufacturing Practice (cGMP)-grade DNA plasmids for vaccines, gene therapies and viral vector production. VGXI, GeneOne’s fully owned subsidiary located in The Woodlands, Texas, has a pre-existing exclusive license with Houston Methodist to develop large-batch RNA manufacturing capacity. Together, the group will generate and test an RNA vaccine against COVID-19.

The Houston Methodist RNA therapeutics research program is led by John Cooke, MD, PhD, Joseph C. “Rusty” Walter and Carole Walter Looke Presidential Distinguished Chair in Cardiovascular Disease Research and professor of Cardiovascular Sciences, and Roman Sukhovershin, MD, PhD, scientific director and assistant research professor of Cardiovascular Sciences. The program designs and generates RNA constructs for the scientific and medical communities in the Texas Medical Center in Houston and across the world. In addition to manufacturing non-GMP and cGMP RNA, scientists in Houston Methodist’s RNA therapeutics research program develop technologies to improve the stability and enhance the delivery of RNA products. They also have the facilities to support testing of RNA products in pre-clinical models, as well as a first-in-man clinical trials unit.

The RNA therapeutics research program at Houston Methodist began as a core group for the Progenitor Cell Biology Consortium of the National Heart, Lung, and Blood Institute and is now also supported by the Cancer Prevention Research Institute of Texas to further the development of cutting-edge RNA technologies for cancer. Funding from GeneOne has permitted the program to expand into vaccines.




Further reading


Research Core Facilities | Houston Methodist


Documentaries, videos and podcasts





Texas Cardiac Arrhythmia Institute at St. David's Medical Center
December 9, 2020
/PRNewswire/ -- Les 3 et 4 décembre 2020, le Texas Cardiac Arrhythmia Institute (TCAI) du St. David's Medical Center a tenu son cinquième symposium...
Texas Cardiac Arrhythmia Institute at St. David's Medical Center
November 25, 2020
/PRNewswire/ -- Les 3 et 4 décembre 2020, le Texas Cardiac Arrhythmia Institute (TCAI) du St. David's Medical Center accueillera EPLive 2020, son cinquième...
August 18, 2020
A preliminary analysis of an ongoing study of more than 300 COVID-19 patients treated with convalescent plasma therapy at Houston Methodist suggests the treatment is safe and effective. The results, which appear now in The American Journal of Pathology, represents one of the first peer-reviewed publications in the country assessing efficacy of convalescent plasma. From March 28, when Houston Methodist Hospital and Research Institute in Houston, Texas became the first academic medical...
June 24, 2020
The US recorded a one-day total of 34,700 new Covid-19 cases, just short of the nations late-April peak of 36,400, according to the count kept by Johns Hopkins University
June 3, 2020
Telangana Today
Five coronavirus positive patients at Gandhi Hospital have received Plasma therapy, as part of the countrywide clinical trials.
Gregory Barber
March 31, 2020
As health care workers prepare for surges of Covid-19 patients, they must grapple with the ethics of rationing critical medical gear.
Kodiak Sciences Inc.
September 15, 2019
PALO ALTO, Calif., Sept. 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel...


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.